|
|
Prepublished online as a Blood First Edition Paper on December 27, 2002; DOI 10.1182/blood-2002-06-1841.
 Previous Article | Table of Contents | Next Article 
Blood, 1 May 2003, Vol. 101, No. 9, pp. 3560-3567
IMMUNOBIOLOGY
Dendritic cells from CML patients have altered actin
organization, reduced antigen processing, and impaired
migration
Rong Dong,
Kate Cwynarski,
Alan Entwistle,
Federica Marelli-Berg,
Francesco Dazzi,
Elizabeth Simpson,
John M. Goldman,
Junia V. Melo,
Robert I. Lechler,
Ilaria Bellantuono,
Anne Ridley, and
Giovanna Lombardi
From the Department of Immunology, Division of
Medicine, and Department of Haematology, Division of Investigative
Science, Faculty of Medicine, Imperial College at Hammersmith Hospital,
London; Transplantation Biology Group, Medical Research
Council (MRC) Clinical Sciences Centre (CSC), Imperial College at
Hammersmith Hospital, London; and The Ludwig Institute for
Cancer Research and Department of Biochemistry and Molecular Biology,
University College, London, United Kingdom.
Chronic myeloid leukemia (CML) is characterized by expression of
the BCR-ABL fusion gene that encodes a 210-kDa protein,
which is a constitutively active tyrosine kinase. At least 70% of the oncoprotein is localized to the cytoskeleton, and several of the most prominent tyrosine kinase substrates for p210BCR-ABL
are cytoskeletal proteins. Dendritic cells (DCs) are bone
marrow-derived antigen-presenting cells responsible for the initiation
of immune responses. In CML patients, up to 98% of myeloid DCs
generated from peripheral blood mononuclear cells are
BCR-ABL positive. In this study we have compared the
morphology and behavior of myeloid DCs derived from CML patients with
control DCs from healthy individuals. We show that the actin
cytoskeleton and shape of CML-DCs of myeloid origin adherent to
fibronectin differ significantly from those of normal DCs. CML-DCs are
also defective in processing and presentation of exogenous antigens
such as tetanous toxoid. The antigen-processing defect may be a
consequence of the reduced capacity of CML-DCs to capture antigen via
macropinocytosis or via mannose receptors when compared with DCs
generated from healthy individuals. Furthermore, chemokine-induced
migration of CML-DCs in vitro was significantly reduced. These
observations cannot be explained by a difference in the maturation
status of CML and normal DCs, because phenotypic analysis by flow
cytometry showed a similar surface expression of maturation makers.
Taken together, these results suggest that the defects in antigen
processing and migration we have observed in CML-DCs may be related to
underlying cytoskeletal changes induced by the p210BCR-ABL
fusion protein.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
S. Mumprecht, C. Claus, C. Schurch, V. Pavelic, M. S. Matter, and A. F. Ochsenbein
Defective homing and impaired induction of cytotoxic T cells by BCR/ABL-expressing dendritic cells
Blood,
May 7, 2009;
113(19):
4681 - 4689.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Q. Sun, C. T. Kong, F. P. Huang, and L. C. Chan
Aberrant dendritic cell differentiation initiated by the Mll-Een fusion gene does not require leukemic transformation
J. Leukoc. Biol.,
January 1, 2008;
83(1):
173 - 180.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. L. Stevens, E. M. Rogers, L. M. Koontz, D. T. Fox, C. C.F. Homem, S. H. Nowotarski, N. B. Artabazon, and M. Peifer
Using Bcr-Abl to Examine Mechanisms by Which Abl Kinase Regulates Morphogenesis in Drosophila
Mol. Biol. Cell,
January 1, 2008;
19(1):
378 - 393.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Yu, C. Liu, K. Su, J. Wang, Y. Liu, L. Zhang, C. Li, Y. Cong, R. Kimberly, W. E. Grizzle, et al.
Tumor Exosomes Inhibit Differentiation of Bone Marrow Dendritic Cells
J. Immunol.,
June 1, 2007;
178(11):
6867 - 6875.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Agrawal, S. Agrawal, J.-N. Cao, H. Su, K. Osann, and S. Gupta
Altered Innate Immune Functioning of Dendritic Cells in Elderly Humans: A Role of Phosphoinositide 3-Kinase-Signaling Pathway
J. Immunol.,
June 1, 2007;
178(11):
6912 - 6922.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Shimizu, M. Hidaka, N. Kadowaki, N. Makita, N. Konishi, K. Fujimoto, T. Uchiyama, F. Kawano, M. Taniguchi, and S.-i. Fujii
Evaluation of the Function of Human Invariant NKT Cells from Cancer Patients Using {alpha}-Galactosylceramide-Loaded Murine Dendritic Cells.
J. Immunol.,
September 1, 2006;
177(5):
3484 - 3492.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. H. Tan, J. B. Yates, S.-A. Xue, C. Chan, W. J. Jordan, J. E. Harper, M. P. Watson, R. Dong, M. A. Ritter, R. I. Lechler, et al.
Creation of tolerogenic human dendritic cells via intracellular CTLA4: a novel strategy with potential in clinical immunosuppression
Blood,
November 1, 2005;
106(9):
2936 - 2943.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Terme, C. Borg, F. Guilhot, C. Masurier, C. Flament, E. F. Wagner, S. Caillat-Zucman, A. Bernheim, A. G. Turhan, A. Caignard, et al.
BCR/ABL Promotes Dendritic Cell-Mediated Natural Killer Cell Activation
Cancer Res.,
July 15, 2005;
65(14):
6409 - 6417.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Linder and P. Kopp
Podosomes at a glance
J. Cell Sci.,
May 15, 2005;
118(10):
2079 - 2082.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Cignetti, A. Vallario, I. Roato, P. Circosta, B. Allione, L. Casorzo, P. Ghia, and F. Caligaris-Cappio
Leukemia-Derived Immature Dendritic Cells Differentiate into Functionally Competent Mature Dendritic Cells That Efficiently Stimulate T Cell Responses
J. Immunol.,
August 15, 2004;
173(4):
2855 - 2865.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Mohty, E. Jourdan, N. B. Mami, N. Vey, G. Damaj, D. Blaise, D. Isnardon, D. Olive, and B. Gaugler
Imatinib and plasmacytoid dendritic cell function in patients with chronic myeloid leukemia
Blood,
June 15, 2004;
103(12):
4666 - 4668.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
